AFP Clinical Answers

COVID-19, Acne Treatment, Threatened Miscarriage, Pilonidal Disease


Am Fam Physician. 2020 Aug 1;102(3):142.

Which chronic diseases are associated with hospitalization or death from COVID-19?

A report from the Centers for Disease Control and Prevention (CDC) summarized coronavirus disease 2019 (COVID-19) cases reported to the CDC from January 22 through May 30, 2020. There were 1,761,503 cases reported and 103,700 deaths. The seven-day average number of cases peaked during this time period in the United States on April 12 (31,994 cases), and daily deaths peaked on April 21 (2,856). The CDC had sufficient information on 287,320 individuals with severe acute respiratory syndrome coronavirus 2 to report outcomes of patients with and without chronic diseases. Cardiovascular disease was present in 32% of patients, diabetes mellitus in 30%, and chronic lung disease in 18%. Of all COVID-19 cases reported to the CDC during this period, 184,673 patients (10.5%) were hospitalized, 29,837 (2%) were admitted to an intensive care unit, and 71,116 (4%) died. The hospitalization rate was six times higher among patients with a chronic disease (45.4% vs. 7.6%), and the death rate was 12 times higher (19.5% vs. 1.6%).

What evidence-based treatments should be used for acne?

Topical retinoids should be used as monotherapy for mild comedonal acne and in combination with other topical or oral agents for moderate to severe inflammatory acne. Systemic antibiotics should be used for treatment of moderate to severe inflammatory acne. Oral isotretinoin should be used for treatment of severe nodular acne or refractory acne in adults and adolescents. Combined oral contraceptives should be considered for menarchal patients unresponsive or intolerant to past therapies, for temporal association of acne outbreaks with menses, or for females with signs and symptoms of hyperandrogenism (e.g., acne, hirsutism, oligomenorrhea). Topical retinoids should be used for maintenance therapy once treatment goals are achieved and oral agents are discontinued.



Copyright © 2020 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions

More in AFP

Editor's Collections

More in Pubmed


May 2022

Access the latest issue of American Family Physician

Read the Issue

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article